The global reproductive hormone market is witnessing unprecedented price pressure, particularly in China’s volume-based procurement (VBP) landscape, where Urofollitropin— a core urinary-derived FSH for assisted reproductive technology (ART)—has become a focal point of cost optimization. As VBP drives aggressive price cuts, many manufacturers face the dilemma of balancing affordability and quality, with some中标 products even priced below production costs1. Kangyuan, leveraging advanced production optimization and scale advantages, is redefining the Urofollitropin price-value equation, delivering high-quality products that comply with VBP requirements while maintaining sustainable profitability and clinical efficacy.

　　As a critical low molecular weight heparin (LMWH) for thrombosis prevention and treatment, Dalteparin Sodium is witnessing a geo-diversified demand landscape, with China emerging as the global production core and emerging markets driving growth. With China accounting for over 60% of global Dalteparin Sodium API capacity2, Jiulong leverages its strategic position in this production hub to deliver geo-adapted solutions, tailoring formulations to regional clinical needs, regulatory standards, and market access requirements. From EU-compliant high-purity products to cost-effective options for Southeast Asia, our Dalteparin Sodium portfolio bridges the gap between global quality standards and local market demands, solidifying Jiulong’s role as a trusted global supplier.

　　Dalteparin Sodium’s clinical applications vary significantly by region, driving the need for geo-tailored formulations— a strength that sets Jiulong apart. In Europe, where Dalteparin Sodium is widely used for post-operative thromboprophylaxis (especially hip replacement surgery) and extended VTE treatment in solid tumor patients1, we offer pre-filled syringes (2500 IU, 5000 IU) compliant with EP standards, optimized for the recommended once-daily dosing regimen. In China, amid national volume-based procurement (VBP) with an average 67% price cut2, our Dalteparin Sodium is formulated for high-volume hospital supply, maintaining 99.5% purity while meeting cost-efficiency requirements for primary care access. For pediatric patients in emerging APAC markets, we provide adjusted dosages aligned with global pediatric VTE treatment guidelines1.

　　Geo-specific regulatory compliance is the cornerstone of Jiulong’s Dalteparin Sodium global strategy, unlocking access to key markets. To penetrate the EU— a high-value market dominated by原研 brands2—we hold EU EDQM CEP certification and align production with Ph. Eur. monographs, ensuring traceability and impurity control. For the U.S. market, we maintain an activated FDA DMF filing, supporting supply for both surgical prophylaxis and renal-compromised patient populations. In Southeast Asia and Latin America, where regulatory pathways are more flexible, we collaborate with local partners to navigate regional GMP norms, reducing market entry time by 30% while ensuring Dalteparin Sodium meets local quality benchmarks.

　　Jiulong’s competitive edge stems from its integration into China’s Dalteparin Sodium production hub, combining scale, cost-efficiency, and advanced technology. Our annual capacity of 120 tons— accounting for 10% of China’s total Dalteparin Sodium output2—enables stable supply even during global raw material volatility. We adopt advanced enzymatic hydrolysis and chromatography purification processes, improving API yield by 15% and reducing unit costs by 22% compared to global averages. This efficiency allows us to offer competitive pricing: EU-compliant formulations at 25% lower than European manufacturers, and VBP-aligned products for China that balance affordability and quality, supported by our full-chain control from porcine raw material sourcing to finished product packaging.